2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Syk

Syk

Spleen tyrosine kinase

Syk

Related Products

PDF 0.56 MB

Syk (Spleen tyrosine kinase) is a cytosolic non-receptor protein tyrosine kinase (PTK) that is expressed at high levels, both in hematopoietic cells (such as mast cells, B lymphocytes, T lymphocytes, neutrophils, dendritic cells, and macrophages) and in non-hematopoietic cells.

Syk mediates key signal transduction pathways following the activation of immune cell receptors. Syk associates with different receptors on the surface of various cells such as B cells, mast cells, monocytes, macrophages, and neutrophils, and even osteoclasts and breast cancer cells. Following the engagement of these receptors with their ligands, SYK is activated and orchestrates diverse cellular responses, including cytokine production (in T cells and monocytes) and phagocytosis (in macrophages).

Syk Related Products (90):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-78263
    MNS
    		Inhibitor 99.55%
    MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells.
    MNS
  • HY-76474A
    BAY 61-3606 hydrochloride
    		Inhibitor 98.08%
    BAY 61-3606 hydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 hydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 hydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. BAY 61-3606 hydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
    BAY 61-3606 hydrochloride
  • HY-174369
    TREM2 agonist-3
    		Activator 99.39%
    TREM2 agonist-3 (Compound 4i) is a TREM2 agonist with a KD value of 19.0 µM. The KD value of TREM2 agonist-3 for TREM1 is 39.8 µM. TREM2 agonist-3 induces an increase in phosphorylated SYK levels. TREM2 agonist-3 can be used in the research of neurodegenerative diseases and other diseases associated with TREM2 dysfunction.
    TREM2 agonist-3
  • HY-13038
    Fostamatinib Disodium
    		Inhibitor 98.94%
    Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib Disodium
  • HY-12736A
    GSK143 dihydrochloride
    		Inhibitor 99.37%
    GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC50=7.1). GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.
    GSK143 dihydrochloride
  • HY-131341
    Syk-IN-4
    		Inhibitor 98.0%
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.
    Syk-IN-4
  • HY-13038B
    Fostamatinib disodium hexahydrate
    		Inhibitor 99.46%
    Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).
    Fostamatinib disodium hexahydrate
  • HY-16420
    R112
    		Inhibitor 98.90%
    R112 is a fast and reversible inhibitor of spleen tyrosine kinase (Syk) kinase. R112 inhibits Syk kinase activity with an IC50 value of 226 nM and a Ki value of 96 nM. R112 inhibits IgE-FcεRI signaling pathway. R112 can be used for the research of allergic rhinitis.
    R112
  • HY-P991734
    VHB937
    		Activator 99.9%
    VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research.
    VHB937
  • HY-136198
    SRX3207
    		Inhibitor 98.50%
    SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.
    SRX3207
  • HY-109082
    Cevidoplenib
    		Inhibitor 99.58%
    Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively.
    Cevidoplenib
  • HY-15999A
    Cerdulatinib hydrochloride
    		Inhibitor 98.96%
    Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.
    Cerdulatinib hydrochloride
  • HY-P6442
    Chemerin15
    		Inhibitor 99.65%
    Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
    Chemerin15
  • HY-112386
    OXSI-2
    		Inhibitor 99.9%
    OXSI-2 is a bioavailable, cell-permeable Syk inhibitor with an EC50 of 313 nM and an IC50 of 14 nM.
    OXSI-2
  • HY-16902
    RO9021
    		Inhibitor 98.88%
    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
    RO9021
  • HY-109091B
    Lanraplenib succinate
    		Inhibitor 98.09%
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
    Lanraplenib succinate
  • HY-15324
    PRT062607 acetate
    		Inhibitor 99.83%
    PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models..
    PRT062607 acetate
  • HY-160142
    UBX-382
    		Inhibitor
    UBX-382 is an orally active BTK PROTAC degrader with a DC50 of 4.56 nM. UBX-382 inhibits B-cell receptor signaling by targeting BTK. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins. UBX-382 inhibits tumor growth in murine xenograft models harboring wild-type or C481S mutant BTK-expressing TMD-8 cells. UBX-382 can be used for the study of B-cell-related blood cancers.
    UBX-382
  • HY-109082A
    Cevidoplenib dimesylate
    		Inhibitor 98.96%
    Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
    Cevidoplenib dimesylate
  • HY-18623
    VI 16832
    		Ligand 99.09%
    VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
    VI 16832